LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

LLY

726.38

-2.12%↓

JNJ

178.17

-0.26%↓

ABBV

212.3

-0.22%↓

UNH

315.05

+1.64%↑

NVO

55.12

-1.82%↓

Search

Biogen Inc

Închisă

SectorSănătate

140.29 0.24

Rezumat

Modificarea prețului

24h

Curent

Minim

140.04

Maxim

141.94

Indicatori cheie

By Trading Economics

Venit

394M

635M

Vânzări

215M

2.6B

P/E

Medie Sector

12.653

35.733

EPS

3.02

Marjă de profit

23.995

Angajați

7,605

EBITDA

457M

1B

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+20.72% upside

Dividende

By Dow Jones

Următoarele câștiguri

29 oct. 2025

Statistici piață

By TradingEconomics

Capitalizare de piață

442M

19B

Deschiderea anterioară

140.05

Închiderea anterioară

140.29

Sentimentul știrilor

By Acuity

31%

69%

92 / 371 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bearish Evidence

Biogen Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

6 sept. 2025, 09:30 UTC

Achiziții, Fuziuni, Preluări

Armani Stuck to the Classics. But His Business Needs a Refresh -- Heard on the Street -- WSJ

6 sept. 2025, 08:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

5 sept. 2025, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

5 sept. 2025, 20:37 UTC

Achiziții, Fuziuni, Preluări

Blue Water: Assets of Auction Include Nationwide Retail Distribution Network of More Than 4,000 Branded Service Stations >BLUWU

5 sept. 2025, 20:37 UTC

Achiziții, Fuziuni, Preluări

Blue Water: Assets of Auction Include Lubricant and Blending Plants Supporting Specialty Fuels and Lubricants >BLUWU

5 sept. 2025, 20:36 UTC

Achiziții, Fuziuni, Preluări

Blue Water: Assets of Auction Include Midstream Infrastructure, Including Pipelines and Terminals Such as the Sour Lake Crude Pipeline >BLUWU

5 sept. 2025, 20:36 UTC

Achiziții, Fuziuni, Preluări

Blue Water: Assets of Auction Include Refineries at Lake Charles, La., Lemont, Ill., Corpus Christi, Texas, With Combined Refining Capacity Exceeding 800,000 Barrels per Day >BLUWU

5 sept. 2025, 20:33 UTC

Achiziții, Fuziuni, Preluări

Blue Water: Proposal Would Provide $3.2B Settlement for Holders of PDVSA 2020 Bonds to Be Paid Either in Cash or in Shrs of Publicly Listed Entity That Will Own Citgo >BLUWU

5 sept. 2025, 20:33 UTC

Achiziții, Fuziuni, Preluări

Blue Water: Proposal Would Provide Cash or Stk Distributions to PDV Holding Inc.'s General Creditors >BLUWU

5 sept. 2025, 20:31 UTC

Achiziții, Fuziuni, Preluări

Blue Water Acquisition Corp. III: Announces Submission of $10B Bid for PDV Holding Inc., Parent of Citgo Petroleum Corp.

5 sept. 2025, 20:20 UTC

Câștiguri

These Stocks Moved the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Kenvue, Guidewire, and More -- Barrons.com

5 sept. 2025, 19:23 UTC

Market Talk

Oil Futures Extend Losses Ahead of OPEC+ Meeting -- Market Talk

5 sept. 2025, 19:22 UTC

Câștiguri

Week's Best: Insurance Costs, Like Sea Levels, Are Rising -- Barrons.com

5 sept. 2025, 19:17 UTC

Market Talk

U.S. Natural Gas Snaps Winning Streak -- Market Talk

5 sept. 2025, 18:59 UTC

Câștiguri

These Stocks Are Moving the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Kenvue, Guidewire, and More -- Barrons.com

5 sept. 2025, 18:35 UTC

Market Talk

BMO Leans Toward September Canada Rate Cut After 'Exceptionally Weak' Jobs Report -- Market Talk

5 sept. 2025, 17:25 UTC

Market Talk

Bets on Hefty Fed Cut Seen as Exaggerated -- Market Talk

5 sept. 2025, 17:20 UTC

Market Talk

U.S. Oil Rig Count Rises By 2 to 414 -- Market Talk

5 sept. 2025, 17:17 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

5 sept. 2025, 17:17 UTC

Market Talk

Bank of Canada Policy Seen Moving to Expansionary Territory -- Market Talk

5 sept. 2025, 17:03 UTC

Market Talk

Bank of Canada Expected to Cut, But Inflationary Pressures Remain a Concern -- Market Talk

5 sept. 2025, 16:39 UTC

Achiziții, Fuziuni, Preluări

Yorkville Acquisition: Commencing at Market Open on Sept 8, Common Stk Will Trade on Nasdaq Under New Ticker Symbol 'MCGA' >YORK

5 sept. 2025, 16:39 UTC

Achiziții, Fuziuni, Preluări

Yorkville Acquisition: Will Be Renamed to Trump Media Group CRO Strategy Upon Closing of Combination Between Yorkville, Trump Media & Technology Group Corp. and Crypto.com >YORK

5 sept. 2025, 16:39 UTC

Achiziții, Fuziuni, Preluări

Yorkville Acquisition Corp.: Announces Ticker Symbol Change to 'MCGA' Ahead of Trump Media Group CRO Strategy, Inc. Listing

5 sept. 2025, 16:39 UTC

Achiziții, Fuziuni, Preluări

Yorkville Acquisition: Outstanding Publicly Traded Units and Warrants Will Trade on Nasdaq Under New Ticker Symbols 'MCGAU' and 'MCGAW', Respectively >YORK

5 sept. 2025, 16:37 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Global Equities Roundup: Market Talk

5 sept. 2025, 16:37 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Global Energy Roundup: Market Talk

5 sept. 2025, 16:37 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Strathcona Buys Up More MEG Shares In Effort to Scuttle Cenovus Deal -- Market Talk

5 sept. 2025, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

5 sept. 2025, 16:16 UTC

Câștiguri

These Stocks Are Moving the Most Today: Broadcom, Nvidia, Lululemon, Tesla, Samsara, Guidewire, and More -- Barrons.com

Comparație

Modificare preț

Biogen Inc Așteptări

Obiectiv de preț

By TipRanks

20.72% sus

Prognoză pe 12 luni

Medie 169.81 USD  20.72%

Maxim 260 USD

Minim 118 USD

În baza a 26 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruBiogen Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

26 ratings

12

Cumpărare

14

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

118.15 / 121.17Suport & Rezistență

Termen scurt

Weak Bearish Evidence

Termen mediu

Weak Bullish Evidence

Termen lung

Weak Bearish Evidence

Sentiment

By Acuity

92 / 371 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Biogen Inc

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS. It offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for non-Hodgkin's lymphoma; and other anti-CD20 therapies. In addition, the company is developing various products for the treatment of MS, Alzheimer's disease and dementia, neuromuscular disorders, Parkinson's disease and movement disorders, neuropsychiatry, genetic neurodevelopmental disorders, and biosimilars, which are under various stages of development. It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc., as well as collaboration with Fujirebio to potentially identify and develop blood-based biomarkers for tau pathology in the brain. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.
help-icon Live chat